TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15976152

Group type: EXPERIMENTAL
Intervention: Child adherence to weighing and preplanning for celebrations where high-fat foods are served; Parent adherence to praising the child and modeling healthy eating habits
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Child adherence to recording food and calories; Parent adherence to modeling healthy eating habits
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Child weighing and preplanning; Parent modeling
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Child recording and parent modeling
Number of subjects: 110
Study: 12888371

Group type: EXPERIMENTAL
Intervention: Active study population (ASP)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Stage-shifting from invasive stage II or worse to invasive stage I
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Stage-shifting from invasive stage I to DCIS
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Assumed stage-shifting from invasive disease to DCIS
Number of subjects: 141

Group type: COMPARATOR
Intervention: Randomised trials of breast cancer screening
Number of subjects: 141
Study: 18425651

Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 76

Group type: COMPARATOR
Intervention: Neutrally-framed message
Number of subjects: 76
Study: 8780614

Group type: EXPERIMENTAL
Intervention: Mammography
Number of subjects: 9477

Group type: COMPARATOR
Intervention: No Mammography
Number of subjects: 9477
Study: 1812497

Group type: EXPERIMENTAL
Intervention: Levoprotiline
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 9
Study: 3888463

Group type: EXPERIMENTAL
Intervention: Timolol treatment (10 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol treatment
Number of subjects: 0
Study: 29936188

Group type: EXPERIMENTAL
Intervention: Risk prediction score including early treatment response
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Risk prediction score
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: External validation of risk prediction score
Number of subjects: 304
Study: 29156488

Group type: EXPERIMENTAL
Intervention: cobimetinib plus vemurafenib
Number of subjects: 210

Group type: COMPARATOR
Intervention: vemurafenib
Number of subjects: 210
Study: 26454105

Group type: EXPERIMENTAL
Intervention: Regular morning hydrocortisone intake
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Postponement of morning hydrocortisone intake
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy matched controls
Number of subjects: 31
Study: 25096769

Group type: EXPERIMENTAL
Intervention: Esmolol infusion (0.5 mg/kg/min)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Esmolol bolus (1.5 mg/kg IV)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (0.9% NaCl)
Number of subjects: 45
Study: 22056980

Group type: EXPERIMENTAL
Intervention: Sugar-free beverages (10% sugar equivalent in taste and appearance)
Number of subjects: 642

Group type: COMPARATOR
Intervention: Sugar-sweetened beverages
Number of subjects: 642
Study: 19168247

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES), n=37
Number of subjects: 75

Group type: COMPARATOR
Intervention: Bare metal stents (BMS), n=38
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both SES and BMS
Number of subjects: 75
Study: 22101221

Group type: EXPERIMENTAL
Intervention: Carboplatin administered by convection-enhanced delivery (CED)
Number of subjects: 18
Study: 16306032

Group type: EXPERIMENTAL
Intervention: Nevirapine 400 mg once daily
Number of subjects: 578

Group type: COMPARATOR
Intervention: Nevirapine 200 mg twice daily
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 578
Study: 12032520

Group type: EXPERIMENTAL
Intervention: DHA+ARA formula
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control (no DHA or ARA)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: DHA formula
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: DHA or DHA+ARA
Number of subjects: 194
Study: 9809131

Group type: EXPERIMENTAL
Intervention: High-dose LAAM (330 mg/week)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low-dose LAAM (165 mg/week)
Number of subjects: 9
Study: 7915916

Group type: EXPERIMENTAL
Intervention: IL‐1 alpha at 3.0 micrograms/m2/d
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IL‐1 alpha treatment
Number of subjects: 40
Study: 2683506

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (cephalosporin)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 80
Study: 1233219

Group type: COMPARATOR
Intervention: Propranolol (40 mg orally)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Metoprolol (40 mg orally)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31517663

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 44 U
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 32 U
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (both dosages)
Number of subjects: 101
Study: 29428459

Group type: EXPERIMENTAL
Intervention: Ritonavir‐boosted protease inhibitor (PI) monotherapy
Number of subjects: 296
Study: 28284200

Group type: EXPERIMENTAL
Intervention: EarlyCDT®-Lung Test followed by X-ray and CT scanning
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Standard clinical practice in the UK
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: EarlyCDT®-Lung Test
Number of subjects: 12000
Study: 26698263

Group type: EXPERIMENTAL
Intervention: Atorvastatin combined with trimetazidine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Atorvastatin alone (Control)
Number of subjects: 90
Study: 24293762

Group type: EXPERIMENTAL
Intervention: NREM sleep (N3) during a post-learning nap
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: REM sleep during a post-learning nap
Number of subjects: 25

Group type: COMPARATOR
Intervention: Wake condition (no nap)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: NREM sleep (N3) in the wake condition
Number of subjects: 25
Study: 21876312

Group type: EXPERIMENTAL
Intervention: Levamisole (100 mg orally for 12 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 36
Study: 18180678

Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol fixed combination (n=23)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2% (n=23)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No treatment (Control group, n=23)
Number of subjects: 43
Study: 17003250

Group type: EXPERIMENTAL
Intervention: Smoking hygiene intervention
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 14636936

Group type: EXPERIMENTAL
Intervention: Misoprostol 600 microg sublingually
Number of subjects: 149

Group type: COMPARATOR
Intervention: Misoprostol 800 microg vaginally
Number of subjects: 149
Study: 10921543

Group type: EXPERIMENTAL
Intervention: Postpyloric paracetamol administration
Number of subjects: 45

Group type: COMPARATOR
Intervention: Gastric paracetamol administration
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Early postpyloric or conventional gastric nutrition in group II
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Paracetamol pharmacokinetic study
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Opiate dose
Number of subjects: 45
Study: 8726596

Group type: COMPARATOR
Intervention: Methylprednisolone, administered early
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: New pharmacologic agents (not specified)
Number of subjects: 10000
Study: 1571340

Group type: EXPERIMENTAL
Intervention: Triple therapy (cyclosporine, azathioprine, and prednisolone)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Steroid withdrawal
Number of subjects: 112

Group type: COMPARATOR
Intervention: Double therapy (cyclosporine and azathioprine)
Number of subjects: 112
Study: 2856757

Group type: EXPERIMENTAL
Intervention: Ovo-lacto-vegetarian (OLV) diet for 6 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual diet maintained throughout 12 weeks
Number of subjects: 58
Study: 28831616

Group type: EXPERIMENTAL
Intervention: HIVST-OIC (home-based HIV self-testing with online counseling)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 430
Study: 27090218

Group type: EXPERIMENTAL
Intervention: Sardine-enriched diet (100 g of sardines 5 days a week for 6 months)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Type 2 diabetes standard diet (control group)
Number of subjects: 35
Study: 25311218

Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy (IFRT)
Number of subjects: 1712

Group type: COMPARATOR
Intervention: No additional therapy
Number of subjects: 1712

Group type: EXPERIMENTAL
Intervention: Dexamethasone, etoposide, cisplatin, and cytarabine (DECA)
Number of subjects: 1712

Group type: COMPARATOR
Intervention: No DECA
Number of subjects: 1712

Group type: EXPERIMENTAL
Intervention: PET-positive results
Number of subjects: 1712

Group type: COMPARATOR
Intervention: PET-negative results
Number of subjects: 1712

Group type: EXPERIMENTAL
Intervention: ABVE-PC chemotherapy
Number of subjects: 1712
Study: 22151619

Group type: EXPERIMENTAL
Intervention: Topical morphine gel
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 20494413

Group type: EXPERIMENTAL
Intervention: Intravesical sodium chondroitin sulfate (2.0% in phosphate-buffered saline)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intravesical sodium chondroitin sulfate
Number of subjects: 65
Study: 18547825

Group type: EXPERIMENTAL
Intervention: Celecoxib (CBX)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aceclofenac (ACF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Celecoxib (CBX) and Aceclofenac (ACF)
Number of subjects: 30
Study: 15647415

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Norfloxacin plus Metronidazole
Number of subjects: 11
Study: 11925275

Group type: EXPERIMENTAL
Intervention: Enhanced Consent (EC) procedure
Number of subjects: 99

Group type: COMPARATOR
Intervention: Routine Consent (RC) procedure
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Normal comparison subjects with Enhanced Consent (EC)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Normal comparison subjects with Routine Consent (RC)
Number of subjects: 99
Study: 10594413

Group type: EXPERIMENTAL
Intervention: Combitube
Number of subjects: 75

Group type: COMPARATOR
Intervention: Tracheal tube
Number of subjects: 75

Group type: COMPARATOR
Intervention: Laryngeal mask airway
Number of subjects: 75
Study: 7560489

Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Inspiratory Resistance-Positive Expiratory Pressure (IR-PEP)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Routine chest physiotherapy alone
Number of subjects: 97
Study: 2360434

Group type: EXPERIMENTAL
Intervention: Rydell nail (n=110)
Number of subjects: 220

Group type: COMPARATOR
Intervention: LIH hook pins (n=110)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Rydell nail (n=30, nondisplaced fractures)
Number of subjects: 220

Group type: COMPARATOR
Intervention: LIH hook pins (n=16, nondisplaced fractures)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Rydell nail (n=48, displaced fractures)
Number of subjects: 220

Group type: COMPARATOR
Intervention: LIH hook pins (n=60, displaced fractures)
Number of subjects: 220
Study: 346189

Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 18

Group type: COMPARATOR
Intervention: Quinacrine
Number of subjects: 18
Study: 31094953

Group type: EXPERIMENTAL
Intervention: Patient and provider education program
Number of subjects: 207
Study: 28425772

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 169

Group type: COMPARATOR
Intervention: Adalimumab, Etanercept, Infliximab
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: ADAb
Number of subjects: 169
Study: 26342556

Group type: EXPERIMENTAL
Intervention: Lixisenatide (2-step group)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Lixisenatide (1-step group)
Number of subjects: 69
Study: 24974134

Group type: EXPERIMENTAL
Intervention: NNS pre‐tube feeding (n=19)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: NNS on onset of tube feeding (n=20)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (n=20)
Number of subjects: 59
Study: 23093481

Group type: EXPERIMENTAL
Intervention: Test tablet (newly formulated with synthetic paraffin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imdur® Long-Acting tablet 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both tablets
Number of subjects: 0
Study: 20042099

Group type: EXPERIMENTAL
Intervention: Telephone survey method
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Mail survey method
Number of subjects: 1700
Study: 17479604

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15908849

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11774096

Group type: EXPERIMENTAL
Intervention: Congenital lactic acidosis (CLA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Previously published cases (79 cases)
Number of subjects: 35
Study: 9407394

Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus tetracycline fibers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 0
Study: 7970009

Group type: EXPERIMENTAL
Intervention: Tizanidine (2 mg to a maximum of 36 mg/d; weeks 2 to 4)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 220
Study: 3620284

Group type: EXPERIMENTAL
Intervention: Triprolidine 2.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dipipanone 8 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of triprolidine 2.5 mg and dipipanone 8 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29546325

Group type: EXPERIMENTAL
Intervention: Savvy Advanced psychoeducation program
Number of subjects: 100
Study: 29677060

Group type: EXPERIMENTAL
Intervention: Impaired cerebral autoregulation during CPB
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Moderate-severe large vessel stenosis
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Small vessel cerebral vascular disease
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Higher average temperature during CPB
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 346

Group type: COMPARATOR
Intervention: Moderate-severe large cerebral arterial stenosis
Number of subjects: 346
Study: 26992271

Group type: COMPARATOR
Intervention: Standard pain control with acetaminophen and opioids (SPC)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Standard pain control plus gabapentin (SPC+G)
Number of subjects: 22
Study: 23903371

Group type: EXPERIMENTAL
Intervention: AMG 416 (velcalcetide) 10 mg or more
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AMG 416 (velcalcetide)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 22171015

Group type: EXPERIMENTAL
Intervention: Adjuvanted A/H1N1 influenza vaccine
Number of subjects: 149
Study: 19381692

Group type: EXPERIMENTAL
Intervention: Behavioral therapy sleep intervention
Number of subjects: 219

Group type: COMPARATOR
Intervention: Healthy eating control group
Number of subjects: 219
Study: 17509744

Group type: EXPERIMENTAL
Intervention: EC40 varnish applied at baseline, 6, 12 and 18 months
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: EC40 varnish applied at baseline, 3, 12 and 15 months
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 2
Study: 15695539

Group type: EXPERIMENTAL
Intervention: High-dose metronidazole (1500 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metronidazole (250 mg three times/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spiramycin/metronidazole combination (250 mg/1 500 000 units, three times/day)
Number of subjects: 0
Study: 12457223

Group type: EXPERIMENTAL
Intervention: Laparoscopic ultrasound
Number of subjects: 135

Group type: COMPARATOR
Intervention: Operative cholangiography
Number of subjects: 135
Study: 10893598

Group type: EXPERIMENTAL
Intervention: Screen detected cases (121 participants)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Historical cases (72 participants)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Screen detected specimens (121 participants)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Screen detected tumors (60% of 121 participants)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Screen detected tumors (50% of 121 participants)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Screen detected tumors (121 participants)
Number of subjects: 121
Study: 8938546

Group type: EXPERIMENTAL
Intervention: Serum laminin
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Serum hyaluronan
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Elevated concentrations of laminin or hyaluronan
Number of subjects: 38
Study: 1586710

Group type: EXPERIMENTAL
Intervention: Cytoxan (120 mg/kg) with total body irradiation (CYTBI)
Number of subjects: 101

Group type: COMPARATOR
Intervention: busulfan (16 mg/kg) (BUSCY)
Number of subjects: 101
Study: 3923941

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy with FT-207 plus OK-432 (group A)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Chemotherapy with only FT-207 (group B)
Number of subjects: 134
Study: 2884859

Group type: EXPERIMENTAL
Intervention: Doxazosin (1 to 16 mg daily)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Atenolol (50 to 100 mg daily)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 129
Study: 31813662

Group type: EXPERIMENTAL
Intervention: Anthracycline-based chemotherapy (epirubicin)
Number of subjects: 78
Study: 30006861

Group type: EXPERIMENTAL
Intervention: s-DVC
Number of subjects: 226

Group type: COMPARATOR
Intervention: d-DVC
Number of subjects: 226
Study: 28493376

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 40 mg
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 80 mg
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study: 26136179

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 90

Group type: COMPARATOR
Intervention: Platelet-poor plasma (PPP) injection
Number of subjects: 90

Group type: COMPARATOR
Intervention: No injection
Number of subjects: 90
Study: 23733236

Group type: EXPERIMENTAL
Intervention: Coronary calcium scores (CS)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Diamond Forrester (DF) scores
Number of subjects: 250
Study: 21291457

Group type: EXPERIMENTAL
Intervention: COPing with and CAring for Infants with Special Needs (COPCA) intervention group (n=21)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Traditional infant physiotherapy (TIP) intervention group (n=25)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Physiotherapeutic actions
Number of subjects: 46
Study: 20076880

Group type: EXPERIMENTAL
Intervention: 70W power
Number of subjects: 15

Group type: COMPARATOR
Intervention: 50W power
Number of subjects: 15
Study: 16805678

Group type: EXPERIMENTAL
Intervention: OFD+EDTA+EMD
Number of subjects: 24

Group type: COMPARATOR
Intervention: OFD+EMD
Number of subjects: 24
Study: 15532360

Group type: EXPERIMENTAL
Intervention: Day 2-Day 2 group (two retention tests administered 23 hr 50 min and 24 hr after practice)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Day 1-Control group (one retention test administered 20 min after practice)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Day 2-Control group (one retention test administered 24 hr after practice)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Day 1-Day 1 group (two retention tests administered 10 min and 20 min after practice)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Day 1-Day 2 group (two retention tests administered 10 min and 24 hr after practice)
Number of subjects: 0
Study: 10936742

Group type: EXPERIMENTAL
Intervention: Dienogest 0.5 mg + Oestradiol valerate 2.0 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dienogest 1.0 mg + Oestradiol valerate 2.0 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dienogest 2.0 mg + Oestradiol valerate 2.0 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dienogest 3.0 mg + Oestradiol valerate 2.0 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dienogest 4.0 mg + Oestradiol valerate 2.0 mg
Number of subjects: 5
Study: 9079579

Group type: EXPERIMENTAL
Intervention: multicomponent smoking cessation intervention (printed guide, video, telephone booster call)
Number of subjects: 0

Group type: COMPARATOR
Intervention: health education materials not directly addressing tobacco use
Number of subjects: 0
Study: 8399091

Group type: EXPERIMENTAL
Intervention: Canola oil-enriched diet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Corn oil-enriched diet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Olive oil-enriched diet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Vegetable oil-enriched diets
Number of subjects: 15

Group type: COMPARATOR
Intervention: Baseline diet
Number of subjects: 15
Study: 3945535

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.6 mg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31504303

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination tablet of sofosbuvir (400 mg) and daclatasvir (60 mg)
Number of subjects: 1361

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination tablet of sofosbuvir and daclatasvir with or without ribavirin
Number of subjects: 1361
Study: 29528504

Group type: EXPERIMENTAL
Intervention: Reappraising the emotion-eliciting stimulus
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Reappraising their emotional response
Number of subjects: 90

Group type: COMPARATOR
Intervention: No specific emotion regulation instructions (Control)
Number of subjects: 90